NewAmsterdam Pharma Co NV (NAMS) PT Raised to $52 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts NAMS Hot Sheet
Price: $20.88 +4.92%
Rating Summary:
16 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 28 | New: 13
Rating Summary:
16 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 28 | New: 13
Join SI Premium – FREE
Cantor Fitzgerald analyst Steve Seedhouse raised the price target on NewAmsterdam Pharma Co NV (NASDAQ: NAMS) to $52.00 (from $49.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Stifel on NewAmsterdam Pharma Co NV (NAMS): 'continue to think the setup here is very compelling and significantly upside-biased'
- Clear Secure Inc (YOU) PT Raised to $80 at Goldman Sachs
- CVS Health (CVS) PT Lowered to $103 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
